Beyond Glycemic Control: Advancing Icovamenib as a Potential Disease- Modifying Therapy for Diabetes & Obesity
10:00 am - Wednesday 9th December 2026
- Demonstrating durable improvements in glycemic control across both type 1 and type 2 diabetes, and supporting the potential restoration of beta-cell function and improvement in mass
- Exploring how icovamenib could complement GLP-1 therapies to deliver improved metabolic outcomes across diabetes and obesity populations
- Uncovering translational evidence of muscle preservation, fat reduction, and enhanced GLP-1 pathway activity to expand icovamenib’s potential beyond glucose management
